Complementary solutions to drive growth with health plans as well as pharma clients, companies say.
Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.
An arduous reimbursement process has put a damper on how quickly patients can receive the drug, say analysts, citing KOLs.
Life expectancy for patients cured of advanced HCV similar to healthy peers: study; Ackman takes a $2 billion stake in animal drugmaker Zoetis; Amgen and AstraZeneca report that brodalumab bested Stelara in psoriasis head-to-head.
The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.
FDA will evaluate effect of pharma commercial barrage; Pfizer settles Neurontin marketing lawsuit for $321 million; AbbVie and Gilead release top-line results on HCV combo therapies.
Developing exclusive features from proven generics is a growing opportunity for patients as much as it is a ploy for life-cycle extension.
An FDA study of Medicare patients found that patients who took Pradaxa showed a reduced risk of stroke and brain hemorrhage.
According to a survey, general practitioners are against new NHS guidelines on prescribing statins.
Orphan drug growth will easily outpace non-orphans through 2020.
The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.